ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
2024年8月16日 - 5:05AM
ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the
size of its board of directors to 11 and has elected Christopher
DelOrefice to the board, effective immediately. Mr. DelOrefice was
appointed during ResMed’s regularly scheduled board meeting on
August 15, 2024, and will stand for re-election with the rest of
ResMed’s directors at its annual meeting on November 21, 2024. Mr.
DelOrefice has also been appointed as a member of ResMed’s board
audit committee.
DelOrefice currently serves as executive vice president and
chief financial officer (CFO) of Becton, Dickinson and Company (BD)
and brings over 30 years of audit, finance, and strategic expertise
to augment and strengthen ResMed’s diverse board. Before joining BD
in September 2021, DelOrefice served in many roles at Johnson &
Johnson (J&J), including most recently as vice president of
investor relations and previously as CFO of J&J’s consumer and
medical device business segments for North America, along with
roles in finance leadership for supply chain, corporate mergers and
acquisitions, consumer research and development, and business
development for J&J’s North America pharmaceutical business.
Before J&J, DelOrefice held positions of increasing
responsibility in accounting, global audit, and financial reporting
at AstraZeneca, AET Films, and Ametek.
“I’m pleased to welcome Christopher DelOrefice to ResMed’s
Board,” said Mick Farrell, Chairman and CEO of ResMed. “Chris has
proven himself an experienced global leader in corporate finance
and business strategy, as well as in global operations management
across multiple business sectors, including in his current role as
CFO of a multi-billion dollar, global MedTech company. My fellow
board members and I were impressed with Chris’ achievements, as
well as his humility, hard-working nature, and leadership
capabilities, all of which are highly relevant to his service as a
ResMed director. Chris’ financial experience in healthcare and
medical technology at BD, J&J, and AstraZeneca will complement
the leaders already serving as ResMed directors.”
DelOrefice holds a Master of Business Administration and a
Bachelor of Science in Accounting from Villanova University. He
remains actively engaged in student career mentoring and
development initiatives at his alma mater. DelOrefice received his
certified public accountant (CPA) license (inactive) from the
Commonwealth of Pennsylvania.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more,
visit ResMed.com and follow @ResMed.
For investors |
For media |
+1 858.836.5971 |
+1 619.510.1281 |
investorrelations@resmed.com |
news@resmed.com |
ResMed (NYSE:RMD)
過去 株価チャート
から 7 2024 まで 8 2024
ResMed (NYSE:RMD)
過去 株価チャート
から 8 2023 まで 8 2024